Citigroup Maintains Buy on Candel Therapeutics, Raises Price Target to $26

Citigroup analyst Yigal Nochomovitz has maintained a 'Buy' rating on Candel Therapeutics (NASDAQ: CADL) and raised the price target from $22 to $26. This adjustment reflects a positive outlook for the company's performance.